Royal DSM, a global science-based company active in health, nutrition and materials, today announces a change in the leadership of its DSM Biomedical unit. Christophe Dardel, President DSM Biomedical, will pursue his career outside DSM.
To ensure the continuing progress in Biomedical, Mr. Gerard de Reuver will assume responsibility for DSM Biomedical with immediate effect until a long-term successor is appointed.
Gerard, a Dutch national, joined DSM in 2002 after obtaining a University degree in Pharmacy & Biology and gaining senior leadership experience at amongst others Pfizer, Unilever, Perstorp, Gemini and Perkin Elmer. He held positions as President DSM Anti-Infectives and Vice President Crisis & Change. From April 2010 until August 2015, he held the position of President DSM Dyneema and played a key role in developing and strengthening the DSM Dyneema organization.
Source: DSM
Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.
The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.
Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.
